IL6 and COVID-19: Findings from this trial might help clarify whether silibinin-based approaches can therapeutically integrate the mechanisms of action of IL-6-targeted monoclonal antibodies (e.g., tocilizumab, sarilumab, siltuximab) and pan-JAK1/2 inhibitors (e.g., baricitinib) to limit the cytokine storm, T-cell lymphopenia, and coagulopathy in the clinical setting of severe COVID-19.